Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis (2016)
- Authors:
- USP affiliated authors: PERIA, FERNANDA MARIS - FMRP ; NUNES, ALTACILIO APARECIDO - FMRP
- Unidade: FMRP
- DOI: 10.1093/annonc/mdw387.29
- Subjects: NEOPLASIAS COLORRETAIS; METÁSTASE NEOPLÁSICA
- Language: Português
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 27, suppl 6, res. 1393P, 2016
- Conference titles: Congress of European Society for Medical Oncology (ESMO)
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PERIA, Fernanda Maris et al. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis. Annals of Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1093/annonc/mdw387.29. Acesso em: 01 mar. 2026. , 2016 -
APA
Peria, F. M., Ungari, A. Q., Santos, F. N. D., Lins-Almeida, T., & Nunes, A. A. (2016). Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis. Annals of Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1093/annonc/mdw387.29 -
NLM
Peria FM, Ungari AQ, Santos FND, Lins-Almeida T, Nunes AA. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis [Internet]. Annals of Oncology. 2016 ; 27[citado 2026 mar. 01 ] Available from: https://doi.org/10.1093/annonc/mdw387.29 -
Vancouver
Peria FM, Ungari AQ, Santos FND, Lins-Almeida T, Nunes AA. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis [Internet]. Annals of Oncology. 2016 ; 27[citado 2026 mar. 01 ] Available from: https://doi.org/10.1093/annonc/mdw387.29 - Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
- Costs analysis of spinal column metastases surgical treatment
- Carcinoma of ampulla of Vater: carcinogenesis and immunophenotypic evaluation
- Estruturação do atendimento para pacientes oncológicos
- Blue Man: Melaninophagia Secondary to Imatinib
- Toxicity of chemotherapy in a patient with bloom syndrome’s diagnosis
- Physicians expertise in geriatric oncology care: a web survey among brazilian medical oncologists
- Analysis of practice of drugs conciliation in elderly patients with cancer
- Fractalkine (C‑X3‑C motif chemokine ligand 1) as a potential biomarker for depression and anxiety in colorectal cancer patients
- Estudo da expressão da pleiotrofina em astrocitomas e oligodendrogliomas e sua correlação com a proliferação celular, densidade microvascular e sobrevida global
Informações sobre o DOI: 10.1093/annonc/mdw387.29 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
